Date: 01 Sep 2012
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
▴ Rasagiline is a second-generation potent, irreversible and selective inhibitor of monoamine-oxidase type B (MAO-B), which has been evaluated for the treatment of Parkinson’s disease.
▴ Rasagiline also possesses neuroprotective properties that are independent of its MAO inhibitory activity. Unlike selegiline, rasagiline has no amphetamine-like metabolites and its major metabolite, l-(R)-aminoindan, has demonstrated favourable pharmacological activity in experimental studies.
▴ Rasagiline has shown significant beneficial effects as monotherapy in the treatment of early Parkinson’s disease. Monotherapy with rasagiline 1 or 2mg once daily significantly attenuated the worsening of symptoms, compared with placebo, in patients with early Parkinson’s disease in a randomised, double-blind trial (n = 404). Furthermore, patients treated with rasagiline for 12 months had less functional decline than patients whose treatment was delayed for 6 months (n = 371).
▴ In patients with moderate-to-advanced disease receiving background therapy with levodopa and additional antiparkinsonian medications (n=1159), rasagiline 0.5 or lmg once daily reduced the daily ‘off’ time by 0.49–0.94 hours relative to that in placebo recipients in two randomised, double-blind trials. The efficacy of rasagiline lmg once daily was similar to entacapone 200mg administered with each levodopa dose.
▴ Rasagiline was generally well tolerated in clinical trials as both monotherapy and when administered with other antiparkinsonian drugs. Adverse events with rasagiline were generally similar in frequency to those seen in placebo or entacapone recipients.
Schrag A, Ben-Shlomo Y, Quinn NP. Cross sectional prevalence survey of idiopathic Parkinson’s disease and Parkinsonism in London. Br Med J 2000; 321(7252): 21–2CrossRef
de Rijk MC, Launer LJ, Berger K, et al. Prevalence of Parkinson’s disease in Europe: a collaborative study of population-based cohorts. Neruology 2000; 54(Suppl. 5): S21–3
Thebault JJ, Guillaume M. Phase I clinical trials of TVP-1012 (rasagiline mesylate), a selective inhibitor of monoamine oxidase B, for treatment of Parkinson’s disease [abstract no. P397]. Mov Disord 1997; 12Suppl. 1: 106
Rasagiline in Parkinson’s disease. Kansas City (MO): Teva Neuroscience Inc., 2004. (Data on file)
Finberg JP, Lamensdorf I, Weinstock M, et al. Pharmacology of rasagiline (N-propargyl-1R-aminoindan). Adv Neurol 1999; 80: 495–9PubMed
Parkinson Study Group. A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study. Arch Neurol 2002 Dec; 59(12): 1937–43CrossRef
Parkinson Study Group, Stern M. A controlled trial of rasagiline in Parkinson’s disease patients with levodopa-related motor fluctuations (PRESTO study) [abstract no. 22]. Ann Neurol 2003; 54Suppl. 7: S27
Rascol O, Brooks D, Melamed E, et al. A comparative randomized study of rasagiline versus placebo or entacapone as adjunct to levodopa in Parkinson’s disease (PD) patients with motor fluctuations (The LARGO Study) [abstract no. P3001]. Eur J Neurol 2003; 10(1): 234CrossRef
Parkinson Study Group. A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease. Arch Neurol 2004 Apr; 61(4): 561–6CrossRef
Giladi N, Rascol O, Brooks DJ, et al. Rasagiline treatment can improve freezing of gait in advanced Parkinson’s disease: a prospective randomized, double blind, placebo and entacapone controlled study [abstract no. P04.137]. Neurology 2004 Apr 28; 62(Suppl. 5): 329–330. Plus poster presented at the 8th Congress of the European Federation of Neurological Sciences; 2004 Sep 4–7; Paris
Stocchi F, LARGO Study Group. Effect of rasagiline on severity of OFF in Parkinson’s disease. Mov Disord 2004 Jun 14; 19(Suppl. 9): 208–9. Plus poster presented at The Movement Disorder Society’s 8th International Congress of Parkinson’s Disease and Movement Disorders; 2004 Jun 13–7; Rome
Schwid SR, Parkinson Study Group. Rasagiline improves quality of life in patients with early Parkinson’s disease [abstract no. P263]. Mov Disord 2002; 17Suppl. 5: 92
Blindauer K, for the Parkinson Study Group. Tyramine challenge to assess the safety of rasagiline monotherapy in a placebo-controlled multicenter trial for early Parkinson’s disease (the TEMPO Study) [abstract no. P05.077]. Neurology 2001; 56Suppl. 3: 345
Teva Neuroscience Inc. Rasagiline reduces ‘Off’ time in Parkinson’s disease patients [media release]. 2003
Teva Neuroscience Inc. Encouraging news about treatment for advanced Parkinson’s disease [media release]. 2003
Drugs & Aging
Volume 22, Issue 1 , pp 83-91
- Cover Date
- Print ISSN
- Online ISSN
- Springer International Publishing
- Additional Links
- Industry Sectors